Evaluation of efficacy and safety of intravenous hydralazine vs. labetalol in pregnancy related hypertension

Hira Ahmed Malik, Zain ul abideen, Mian Faiz Rasool


Objective: The aim of this study was to evaluate the efficacy and safety of intravenous hydralazine in comparison with labetalol in pregnancy related hypertension.

Place and Duration of Study: This study was carried out in a duration of 9 months from February 2019 to October 2019 in medical departments of Indus hospital Karachi.

Study type: Comparative study.

Materials and methods: A total of 152 patients were selected for this study and two groups were formed. One was hydralazine group and other was labetalol group. Initial reading of blood pressure was done followed by a dose of hydralazine in one group and labetalol in other group. After that side effects, dose and time required to achieve the desired blood pressure was noted.

Results: 69.5% of the patients in hydralazine group achieved the required blood pressure with the 1st dose. Significantly higher number of 81.5% was seen in case of labetalol group who achieved desired blood pressure with 1st dose. Results of our study showed that rapid control of blood pressure is achieved with labetalol as compared to hydralazine. Side effects were also noted in both groups.

Conclusion: It was concluded from our study that both drugs were efficient in decreasing the blood pressure in pregnancy related hypertension to desired levels. However, labetalol is superior and more efficient in decreasing blood pressure as compared to hydralazine.


Hydralazine, Labetalol, Pregnancy related hypertension

Full Text:



Lori JR, Strake AE. A critical analysis of maternal morbidity and mortality in Liberia, West Africa. Midwifery. 2012;25:67–72.

Magee LA, Abalos E, von Dadelszen P, et al. How to manage hypertension in pregnancy effectively. Br J Clin Pharmacol Soc. 2011;72:394–401.

Delgado De Pasquale S, Velarde R, Reyes O, et al. Hydralazine vs labetalol for the treatment of severe hypertensive disorders of pregnancy. A randomized, controlled trial. Pregnancy Hypertens. 2013;4(1):19–22.

Sharma KJ, Rodriguez M, Kilpatrick SJ, et al. Risks of parenteral antihypertensive therapy for the treatment of severe maternal hypertension are low. Hypertens Pregnancy. 2016;35(1):123–8.

Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2013;7:CD001449. doi:10.1002/14651858.CD001449.pub3.

Magee LA. Drugs in pregnancy. Antihypertensives. Best Pract Res Clin Obstet Gynaecol. 2001;15(6):827–45.

Magee LA, Cham C, Waterman EJ, et al. Hydralazine for treat- ment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003;327:955–60.

Nombur LI, Agida ET, Isah AY, et al. A comparison of hydra- lazine and labetalol in the management of severe preeclampsia. J Women’s Health Care. 2014;3:200.

Swati T, Lila V, Lata R, et al. A comparative study of IV labe- talol and IV hydralazine on mean arterial blood pressure changes in pregnant women with hypertensive emergency. Sch J Appl Med Sci. 2016;4(6F):2256–9.

Holbrrok Brad, Nirgudkar Pranita, Mozurkewich Ellen. Efficacy of hydralazine, labetalol, and nifedipine for the acute reduction of severe hypertension in pregnancy: a systematic review. AJOG. 2015;212(1):s286–7.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.